WallStSmart
ACHL

Achilles Therapeutics PLC ADR

NASDAQ: ACHL · HEALTHCARE · BIOTECHNOLOGY

$1.48
+0.00% today

Updated 2026-06-05

Market cap
$63.22M
P/E ratio
P/S ratio
EPS (TTM)
$-1.66
Dividend yield
52W range
$0 – $0
Volume
1.2M

Achilles Therapeutics PLC ADR (ACHL) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item201820192020202120222023
Total assets$13.96M$105.20M$218.92M$317.11M$220.36M$161.46M
Cash & equivalents$10.68M$97.59M$177.85M$266.32M$173.34M$131.54M
Current assets$13.38M$103.06M$187.80M$284.75M$196.58M$145.63M
Total liabilities$1.29M$3.86M$29.55M$27.58M$23.31M$19.09M
Current liabilities$1.29M$3.86M$16.62M$19.11M$17.99M$17.00M
Long-term debt
Shareholder equity$12.67M$101.35M$189.37M$289.53M$197.04M$142.37M
Retained earnings$-10.82M$-24.81M$-58.01M$-119.11M$-190.29M$-259.95M
Accounts receivable$2.46M$4.49M$7.34M$11.17M$16.00M$10.35M
Inventory$504000.00$1.76M$5.13M$4.62M$1.00
Goodwill

Frequently asked questions

How much free cash flow does ACHL generate?

ACHL produced $-49.55M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is ACHL's balance sheet healthy?

ACHL holds $131.54M in cash and equivalents against — in long-term debt, on $142.37M of shareholder equity. That debt is best read against the cash flow the business throws off each year.